Hormuz, Pharma Supply Chains, and the BCP Gap

The Scene Nobody Connected

A pharmacist in Germantown, Ohio fills prescriptions on a Tuesday morning. Shelves are stocked. Business is normal. Half a world away, 230 oil tankers sit stranded in the Persian Gulf, unable to move. These two scenes look unrelated. They are not.

On February 28, 2026, the United States and Israel launched coordinated airstrikes on Iran under Operation Epic Fury. Within days, Iran responded by effectively closing the Strait of Hormuz — the narrow waterway through which roughly one-fifth of the world's oil and gas passes. Brent crude surpassed $100 per barrel by March 8, peaking at $126 — the largest monthly oil price increase in recorded history (Wikipedia, 2026). The US subsequently imposed a naval blockade on vessels entering and exiting Iranian ports (Al Jazeera, 2026).

This is the largest disruption to world energy supply since the 1970s. And most pharmaceutical companies were not ready for it.

The Hidden Dependency

The connection between a Middle Eastern chokepoint and a pill bottle in Ohio runs through India. Nearly 47% of all generic prescriptions dispensed in the United States originate from Indian manufacturers (CNBC, 2026). India, in turn, relies on the Strait of Hormuz for approximately 40% of its crude oil imports — oil that feeds directly into the petrochemical inputs essential to drug manufacturing (CNBC, 2026).

The supply chain runs like this: Gulf oil → petrochemical feedstocks → Indian API (Active Pharmaceutical Ingredient) manufacturing → finished generic medicines → US and European pharmacies. Disrupt the first link and the whole chain shudders.

The damage was not limited to sea routes. Dubai, Abu Dhabi, and Doha — the world's primary cold-chain air cargo hubs connecting Asia, Africa, and Europe — were effectively knocked out. Global air cargo capacity dropped 79% in the Gulf region within the first three days of the conflict, causing a 22% reduction in worldwide air freight capacity (Think Global Health, 2026). For temperature-sensitive medicines — biologics, vaccines, cancer treatments — there was suddenly no viable corridor.

By April 2026, Iranian officials raised the possibility of also disrupting the Bab al-Mandeb Strait on the Red Sea, which would cut off the primary India-to-Europe shipping route, forcing rerouting around the Cape of Good Hope (PharmExec, 2026).

What Is Already Breaking

The pressure is most acute on generic medicines, which account for 85% of prescriptions in both the US and UK, and which operate on razor-thin margins that cannot absorb shipping cost spikes (Supply Chain Magazine, 2026). War-risk insurance premiums for Hormuz transits surged over 1,000% from late February onward (Think Global Health, 2026). For generics manufacturers, this is not an inconvenience — it is an existential margin squeeze.

Specific drugs are already flagged: 48% of global amoxicillin oral suspension is produced in Jordan; 73% of the flumazenil API — a critical anesthetic reversal agent — comes from Israel and Jordan combined (PharmExec, 2026). Cold-chain biologics face compounding pressure from both the sea closure and the air hub collapse. In the UK, aspirin shortages began manifesting as early as December 2025, with frontline pharmacists reporting cost increases of 1,000% by January 2026 (Supply Chain Magazine, 2026).

Where BCP Should Have Stepped In

Business Continuity Planning (BCP) is defined under ISO 22301:2019 as the process of developing systems that allow an organisation to prevent, prepare for, and recover from disruptive incidents. Most pharmaceutical BCPs, however, were built around operational disruptions: factory fires, cyberattacks, pandemics. Geopolitical chokepoint closure is a fundamentally different category of risk.

Christopher and Peck (2004) identified four dimensions of supply chain resilience: re-engineering, agility, collaboration, and culture. The pharmaceutical industry scores poorly on the first two when it comes to geopolitical risk. Re-engineering requires geographic diversification of suppliers, but regulatory requalification of new API sources under FDA or EMA frameworks can take months to years — meaning switching suppliers is not an option in a crisis, only before one. Agility requires rapid rerouting capacity; without pre-qualified alternatives, there is nothing to route to.

Sheffi (2005) argued that the lean manufacturing philosophy — universally adopted in pharma to reduce inventory costs — creates a direct tradeoff with resilience. A 30-to-60-day inventory buffer, the industry standard cited by most distributors (CNBC, 2026), is not a strategic resilience position. It is a countdown timer.

The Kraljic Matrix offers a practical tool here: classifying inputs by supply risk and profit impact. For pharmaceutical companies, petrochemical feedstocks and single-source APIs sit firmly in the "strategic" quadrant — high risk, high impact — and demand dual-sourcing, buffer stocking, and formal scenario planning. Few companies treated them that way.

What Good Looks Like

A BCP designed to handle events like the 2026 Hormuz crisis would include several elements that most current plans lack:

Geopolitical scenario planning embedded formally in the Business Continuity Management System (BCMS), not treated as a foreign policy issue. The Strait of Hormuz has been identified as the world's most critical energy chokepoint for decades — its closure was a foreseeable scenario, not a black swan.

Pre-qualified backup suppliers in geographically diverse locations, with regulatory approval secured in advance. This is expensive. It is less expensive than a supply collapse.

Strategic inventory above lean targets for critical APIs and finished doses, especially those with long lead times or narrow supplier bases.

Supplier BCP auditing — contractually requiring key suppliers to maintain and share their own continuity plans, including exposure to the same chokepoints.

Insurance structures that account for war-risk premiums as a modeled scenario, not a surprise line item.

The SME Problem

Large multinational pharmaceutical companies — Pfizer, Novartis, Roche — have the infrastructure to absorb disruption, reroute logistics, and ride out cost spikes. The companies manufacturing the bulk of what people actually take — small and mid-size generics producers — do not. Their margins were thin before the crisis. A 1,000% insurance surcharge and a six-week reroute around the Cape of Good Hope may simply make production uneconomic.

For these companies, scaled BCP is not optional — it is survival planning. Industry-level responses, including shared strategic stockpiles, collective supplier qualification programmes, and government-backed buffer inventory schemes, are the structural solutions that individual SME BCPs cannot replace on their own.

Conclusion: Geopolitical Risk Is Operational Risk

The 2026 Hormuz crisis did not come without warning. Tensions had been escalating for years. Nuclear negotiations had failed. Iran had signalled potential disruptions repeatedly (Wikipedia, 2026). The signals were there. What was missing, for most organisations, was a BCP that took those signals seriously and translated them into operational preparation.

The Strait of Hormuz is not a geopolitical abstraction for pharmaceutical companies. It is a procurement variable, a logistics dependency, and a supply risk that belongs in every BCMS alongside cyberattacks and natural disasters. Companies that understood this before February 28, 2026 are still filling orders. Those that did not are counting down their buffer stock.

References

Al Jazeera. (2026, April 14). No ships 'make it past' US blockade in Hormuz strait in first day: Pentagon. https://www.aljazeera.com/news/2026/4/14/no-ships-make-it-past-us-blockade-in-hormuz-strait-in-first-day-pentagon

CNBC. (2026, March 16). Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk. https://www.cnbc.com/2026/03/16/strait-of-hormuz-closure-generic-drug-prescriptions.html

Christopher, M., & Peck, H. (2004). Building the resilient supply chain. International Journal of Logistics Management, 15(2), 1–13.

PharmExec. (2026, April). Medical supply chains at risk over escalating conflicts in Iran: Report. https://www.pharmexec.com/view/medical-supply-chains-risk-over-escalating-conflicts-iran-report

Sheffi, Y. (2005). The resilient enterprise: Overcoming vulnerability for competitive advantage. MIT Press.

Supply Chain Magazine. (2026). How conflict reveals pharma supply chain vulnerabilities. https://supplychaindigital.com/news/conflict-reveals-pharma-supply-chain-vulnerabilities

Think Global Health. (2026, March 20). Where the Iran war could disrupt pharmaceutical supply chains. https://www.thinkglobalhealth.org/article/where-the-iran-war-could-disrupt-pharmaceutical-supply-chains